f Evidence for the Interplay between Inflammation and Clotting System in the Pathogenetic Chain of Pulmonary Embolism: A Potential Therapeutic Target to Prevent Multi-organ Failure and Residual Thrombotic Risk

References

1. BurnsSK HaramatiLB Diagnostic imaging and risk stratification of patients with acute pulmonary embolism.Cardiol Rev20122010152410.1097/CRD.0b013e31822d2a6a 22143281
   [Google Scholar]
2. KonstantinidesS.V. MeyerG. BecattiniC. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS).Eur. Heart J.202041454360310.1093/eurheartj/ehz405 31504429
   [Google Scholar]
3. WellsP.S. AndersonD.R. RodgerM. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis.N. Engl. J. Med.2003349131227123510.1056/NEJMoa023153 14507948
   [Google Scholar]
4. DarwishI. FareedJ. BrailovskyY. Dysregulation of biomarkers of hemostatic activation and inflammatory processes are associated with adverse outcomes in pulmonary embolism.Clin. Appl. Thromb. Hemost.2022281076029621106489810.1177/10760296211064898 35043658
   [Google Scholar]
5. EagletonM.J. HenkeP.K. LukeC.E. Inflammation and intimal hyperplasia associated with experimental pulmonary embolism.J. Vasc. Surg.200236358158810.1067/mva.2002.126556 12218985
   [Google Scholar]
6. ImielaA.M. MikołajczykT.P. GuzikT.J. PruszczykP. Acute pulmonary embolism and immunity in animal models.Arch. Immunol. Ther. Exp.202472120240003Epub ahead of print10.2478/aite‑2024‑0003 38299563
   [Google Scholar]
7. LiM. ZhaoX-Y. KouY. KouJ.J. Role of HMGB1 in the formation of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism.Eur. Rev. Med. Pharmacol. Sci.202226207605761510.26355/eurrev_202210_30036 36314346
   [Google Scholar]
8. ZdanyteM. BorstO. MünzerP. NET-(works) in arterial and venous thrombo-occlusive diseases.Front. Cardiovasc. Med.202310115551210.3389/fcvm.2023.1155512 37283578
   [Google Scholar]
9. RezabakhshA. MojtahediF. Tahsini TekantapehS. MahmoodpoorA. AlaA. SoleimanpourH. Therapeutic impact of tocilizumab in the setting of severe COVID-19; An updated and comprehensive review on current evidence.Arch. Acad. Emerg. Med.2024121e4710.22037/aaem.v12i1.2217 38994467
   [Google Scholar]
10. DingJ. YueX. TianX. LiaoZ. MengR. ZouM. Association between inflammatory biomarkers and venous thromboembolism: A systematic review and meta-analysis.Thromb. J.20232118210.1186/s12959‑023‑00526‑y 37525162
    [Google Scholar]
11. BontekoeE. BrailovskyY. HoppensteadtD. Upregulation of inflammatory cytokines in pulmonary embolism using biochip-array profiling.Clin. Appl. Thromb. Hemost.2021271076029621101310710.1177/10760296211013107 33969714
    [Google Scholar]
12. BuonaceraA. StancanelliB. ColaciM. MalatinoL. Neutrophil to lymphocyte ratio: An emerging marker of the relationships between the immune system and diseases.Int. J. Mol. Sci.2022237363610.3390/ijms23073636 35408994
    [Google Scholar]
13. RegoloM. VaccaroM. SorceA. Neutrophil-to-lymphocyte ratio (NLR) is a promising predictor of mortality and admission to intensive care unit of COVID-19 patients.J. Clin. Med.2022118223510.3390/jcm11082235 35456328
    [Google Scholar]
14. ZanoliL. GaudioA. MikhailidisD.P. Vascular dysfunction of COVID-19 is partially reverted in the long-term.Circ. Res.202213091276128510.1161/CIRCRESAHA.121.320460 35345906
    [Google Scholar]
15. RegoloM. SorceA. VaccaroM. Assessing humoral immuno-inflammatory pathways associated with respiratory failure in COVID-19 patients.J. Clin. Med.20231212405710.3390/jcm12124057 37373750
    [Google Scholar]
16. PhanT. BrailovskyY. FareedJ. HoppensteadtD. IqbalO. DarkiA. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict all-cause mortality in acute pulmonary embolism.Clin. Appl. Thromb. Hemost.202026107602961990054910.1177/1076029619900549 31960711
    [Google Scholar]
17. TangS. HuY. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as predictors of mortality in acute pulmonary embolism: A systematic review and meta-analysis.Pak. J. Med. Sci.20244061274127910.12669/pjms.40.6.8802 38952504
    [Google Scholar]
18. TeodoruM. NegreaM.O. CozgareaA. CozmaD. BoiceanA. Enhancing pulmonary embolism mortality risk stratification using machine learning: The role of the neutrophil-to-lymphocyte ratio.J. Clin. Med.2024135119110.3390/jcm13051191 38592029
    [Google Scholar]
19. GaoX. ChenH. HuangZ. LinJ. HuangJ. ChenQ. Correlation between neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio with risk stratification indicators and thrombus burden in patients with moderate-to-high risk acute pulmonary embolism, and changes after treatment.Clin. Appl. Thromb. Hemost.2024301076029624128544610.1177/10760296241285446 39279323
    [Google Scholar]
20. SiddiquiF. TafurA. HussainM. The prognostic value of blood cellular indices in pulmonary embolism.Am. J. Hematol.20249991704171110.1002/ajh.27379 38816957
    [Google Scholar]
21. VanniS. JiménezD. NazerianP. Short-term clinical outcome of normotensive patients with acute PE and high plasma lactate.Thorax201570433333810.1136/thoraxjnl‑2014‑206300 25661114
    [Google Scholar]
22. ZąbczykM. NatorskaJ. Janion-SadowskaA. MalinowskiK.P. JanionM. UndasA. Elevated lactate levels in acute pulmonary embolism are associated with prothrombotic fibrin clot properties: Contribution of NETs formation.J. Clin. Med.20209495310.3390/jcm9040953 32235490
    [Google Scholar]
23. BecattiniC. VedovatiM.C. ColomboS. Identification of hemodynamically stable patients with acute pulmonary embolism at high risk for death: External validation of different models.J. Thromb. Haemost.20242292502251310.1016/j.jtha.2024.04.025 38810699
    [Google Scholar]
24. Di MarcaS. CiliaC. CampagnaA. Comparison of wells and revised geneva rule to assess pretest probability of pulmonary embolism in high‐risk hospitalized elderly adults.J. Am. Geriatr. Soc.20156361091109710.1111/jgs.13459 26032745
    [Google Scholar]